High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of outcome - Lymphoma Working Party of the European Group for blood and marrow transplantation

Journal of Clinical Oncology

Volumn 26, Issue 2, 2008, Pages 218-224

  Kyriakou, Charalampia ^a   Canals, Carmen ^b   Goldstone, Anthony ^b   Caballero, Dolores ^b   Metzner, Bernd ^b   Kobbe, Guido ^b   Kolb, Hans Jochem ^b   Kienast, Joachim ^b   Reimer, Peter ^b   Finke, Jurgen ^b   Oberg, Gunnar ^b   Hunter, Ann ^b   Theorin, Niklas ^b   Sureda, Anna ^b   Schmitz, Norbert ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; THIOTEPA;

ACUTE GRAFT REJECTION; ADULT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 38349193397     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.6219     Document Type: Article

References (43)

1. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
2. Rudiger T, Weisenburger DD, Anderson JR, et al: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13:140-149, 2002
3. Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76-82, 1998
4. Steinberg AD, Seldin MF, Jaffe ES, et al: NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 108:575-584, 1988
5. Pautier P, Devidas A, Delmer A, et al: Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: Outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 32: 545-552, 1999
6. Awidi AS, Tarawneh MS, Abu Khalaf MS, et al: Therapeutic effect of vincristine, adriamycin and prednisolone (VAP) in angioimmunoblastic lymphadenopathy (AIL). Cancer Chemother Pharmacol 10:221-222, 1983
7. Colbert N, Andrieu JM, Bernard J: Pulse methylprednisolone therapy in angioimmunoblastic lymphadenopathy. Acta Haematol 68:307-308, 1982
8. Siegert W, Agthe A, Griesser H, et al: Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen: A multicenter study. Kiel Lymphoma Study Group Ann Intern Med 117:364-370, 1992
9. Quintini G, Iannitto E, Barbera V, et al: Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. Hematol J 2:393-395, 2001
10. Gerlando Q, Barbera V, Ammatuna E, et al: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone. Haematologica 85:880-881, 2000
11. Sallah AS, Bernard S: Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine. Ann Hematol 73: 295-296, 1996
12. Sallah S, Wehbie R, Lepera P, et al: The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Br J Haematol 104:163-165, 1999
13. Bourgeois E, Auxenfants E, Jouffrey C, et al: [Efficacy of fludarabine in the treatment of angioimmunoblastic lymphoma (AIL)]. Ann Med Interne (Paris) 151:230-231, 2000
14. Feremans WW, Khodadadi E: Alpha-interferon therapy in refractory angioimmunoblastic lymphadenopathy. Eur J Haematol 39:91, 1987
15. Hast R, Gustafsson B: Improved response to chemotherapy after interferon alpha-2b in angioimmunoblastic lymphadenopathy (AILD). Eur J Haematol 46:51-52, 1991
16. Hast R, Jacobsson B, Petrescu A, et al: Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 34:597-601, 1999
17. Schwarzmeier JD, Reinisch WW, Kurkciyan IE, et al: Interferon-alpha induces complete remission in angioimmunoblastic lymphadenopathy (AILD): Late development of aplastic anaemia with cytokine abnormalities. Br J Haematol 79:336-337, 1991
18. Siegert W, Nerl C, Meuthen I, et al: Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: Results in 12 patients. Leukemia 5:892-895, 1991
19. Advani R, Warnke R, Sikic BI, et al: Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol 8:601-603, 1997
20. Takemori N, Kodaira J, Sato T, et al: Successful treatment of IBL-like T-cell lymphoma with cyclosporin A: Two case reports with special reference to serum cytokine levels. Hum Cell 13:35-42, 2000
21. Murayama T, Imoto S, Takahashi T, et al: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer 69:2567-2570, 1992
22. Strupp C, Aivado M, Germing U, et al: Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports. Leuk Lymphoma 43:133-137, 2002
23. Dogan A, Ngu LS, Ng SH, et al: Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia 19:873-875, 2005
24. Schetelig J, Fetscher S, Reichle A, et al: Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88:1272-1278, 2003
25. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
26. Kaplan E, Meier P: Non-parmametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Klein JP, Rizzo JD, Zhang MJ, et al: Statistical methods for the analysis and presentation of the results of bone marrow transplants: Part I - Unadjusted analysis. Bone Marrow Transplant 28:909-915, 2001
28. Klein JP, Rizzo JD, Zhang MJ, et al: Statistical methods for the analysis and presentation of the results of bone marrow transplants: Part 2 - Regression modeling. Bone Marrow Transplant 28:1001-1011, 2001
29. Pellatt J, Sweetenham J, Pickering RM, et al: A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol 81:267-272, 2002
30. Reiser M, Josting A, Soltani M, et al: T-cell non-Hodgkin's lymphoma in adults: Clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 43:805-811, 2002
31. Schmitz N, Prange E, Haferlach T, et al: High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Bone Marrow Transplant 8:503-506, 1991
32. Blystad AK, Enblad G, Kvaloy S, et al: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27:711-716, 2001
33. Lindahl J, Kimby E, Bjorkstrand B, et al: High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD. Leuk Res 25:267-270, 2001
34. Rodriguez J, Munsell M, Yazji S, et al: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19:3766-3770, 2001
35. Kyriakou C, Attygalle A, Linch D, and Babis. Angioimmunoblastic T-Cell Lymphoma: A Large Series Outcome Analysis. Blood 106 Issue 11, 2005. (abstr 2810)
36. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
37. Kaiser U, Uebelacker I, Abel U, et al: Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 20:4413-4419, 2002
38. Corradini P, Dodero A, Zallio F, et al: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004
39. Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185-187, 2001
40. Czuczman MS, Porcu P, Johnson J, et al: Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma 48:97-103, 2007
41. Dang NH, Pro B, Hagemeister FB, et al: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136:439-447, 2007
42. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920-2924, 2004
43. Weidmann E, Hess G, Krause SW. Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin (Campath-FCD) is an effective first-line regimen in peripheral T-cell lymphoma. Blood 104, 2004 (abstr 2640)